Loading…
MARKETS
TOOLS
LEARN
Equiscale · Syntellia LLC
Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of engineered antibodies for the treatment of cancer and autoimmune diseases. The company provides Ultomiris to treat patients with atypical hemolytic uremic syndrome, generalized myasthenia gravis, and neuromyelitis optica spectrum disororder; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It also develops XmAb819, a bispecific antibody to treat renal cell carcinoma; XmAb541, which is in Phase I for the treatment of ovarian cancer; XmAb808, a bispecific antibody that binds to the broadly expressed tumor antigen; XmAb942, which is in clinical development for patients with Crohn's disease and ulcerative colitis; Plamotamab, a bispecific T-cell, which is in Phase Ib study to treat rheumatoid arthritis; and XmAb657 for patients with idiopathic inflammatory myopathies. Further, the company develops Xaluritamig, a bispecific T-cell engager that treats prostate cancer; ASP2138 to treat gastric, gastroesophageal junction, and pancreatic cancers; JNJ-9401 to treat metastatic castration-resistant prostate cancer; Obexelimab, an antibody to treat patients with autoimmune diseases; Tobevibart, a treatment for chronic hepatitis Delta; Zaltenibart to treat paroxysmal nocturnal hemoglobinuria and other alternative pathway disorders; Teropavimab and zinlirvimab to treat human immunodeficiency virus; Novartis, an antibody drug candidate that uses XmAb Fc technologies; and JNJ-1493 to treat B-cell malignancies. The company was incorporated in 1997 and is headquartered in Pasadena, California.
Rule-based from financial data. Not advice.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $126M | $-47M | $-92M | $-138M | -14.5% | 13.7% | -60.5% |
| 2024 | $110M | $-186M | $-233M | $-212M | -34.3% | -36.7% | 74.7% |
| 2023 | $175M | $-102M | $-133M | $-99M | -20.1% | 6.1% | 141.3% |
| 2022 | $165M | $-46M | $-55M | $-19M | -7.6% | - | - |
| 2021 | - | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total Revenue | - | 164.58 | 174.62 | 110.49 | 125.58 |
| Operating Revenue | - | 164.58 | 174.62 | 110.49 | 125.58 |
| Operating Expense | - | 247.05 | 306.98 | 288.90 | 303.08 |
| Research And Development | - | 199.56 | 253.60 | 227.69 | 239.43 |
| Selling General And Administration | - | 47.49 | 53.38 | 61.22 | 63.64 |
| Total Expenses | - | 247.05 | 306.98 | 288.90 | 303.08 |
| Operating Income | - | -82.47 | -132.36 | -178.41 | -177.50 |
| Total Operating Income As Reported | - | -82.47 | -132.36 | -178.41 | -177.50 |
| EBITDA | - | -45.70 | -101.96 | -186.17 | -47.19 |
| Normalized EBITDA | - | -68.99 | -101.56 | -134.32 | -139.54 |
| EBIT | - | -54.50 | -113.46 | -198.28 | -57.71 |
| Interest Income | - | 4.83 | 19.33 | 31.93 | 27.52 |
| Interest Expense | - | 0.01 | 6.18 | 36.64 | 31.93 |
| Net Interest Income | - | 4.82 | 13.15 | -4.71 | -4.40 |
| Other Non Operating Income Expenses | - | -0.15 | -0.03 | 0.05 | -0.07 |
| Other Income Expense | - | 23.15 | -0.43 | -51.80 | 92.27 |
| Interest Income Non Operating | - | 4.83 | 19.33 | 31.93 | 27.52 |
| Interest Expense Non Operating | - | 0.01 | 6.18 | 36.64 | 31.93 |
| Net Non Operating Interest Income Expense | - | 4.82 | 13.15 | -4.71 | -4.40 |
| Pretax Income | - | -54.51 | -119.63 | -234.92 | -89.63 |
| Tax Provision | - | 0.67 | 13.66 | 1.62 | 2.50 |
| Tax Rate For Calcs | - | 0 | 0 | 0 | 0 |
| Tax Effect Of Unusual Items | - | 4.89 | -0.08 | -10.89 | 19.39 |
| Net Income Continuous Operations | - | -55.18 | -133.30 | -236.54 | -92.14 |
| Net Income From Continuing And Discontinued Operation | - | -55.18 | -133.13 | -232.62 | -91.92 |
| Net Income From Continuing Operation Net Minority Interest | - | -55.18 | -133.13 | -232.62 | -91.92 |
| Net Income | - | -55.18 | -133.13 | -232.62 | -91.92 |
| Net Income Common Stockholders | - | -55.18 | -133.13 | -232.62 | -91.92 |
| Net Income Including Noncontrolling Interests | - | -55.18 | -133.30 | -236.54 | -92.14 |
| Normalized Income | - | -73.58 | -132.82 | -191.65 | -164.88 |
| Diluted NI Availto Com Stockholders | - | -55.18 | -133.13 | -232.62 | -91.92 |
| Basic Average Shares | - | 59.65 | 60.50 | 65.04 | 74.24 |
| Diluted Average Shares | - | 59.65 | 60.50 | 65.04 | 74.24 |
| Reconciled Depreciation | - | 8.80 | 11.50 | 12.11 | 10.51 |
| Total Unusual Items | - | 23.30 | -0.40 | -51.85 | 92.34 |
| Total Unusual Items Excluding Goodwill | - | 23.30 | -0.40 | -51.85 | 92.34 |
| Minority Interests | - | 0 | 0.16 | 3.92 | 0.21 |
| Special Income Charges | - | -0.14 | 0 | -20.43 | -9.17 |
| Write Off | - | 0.14 | 0 | 20.43 | 9.17 |
| Gain On Sale Of Security | - | 23.43 | -0.40 | -31.42 | 101.51 |
| General And Administrative Expense | - | 47.49 | 53.38 | 61.22 | 63.64 |
| Other Gand A | - | 47.49 | 53.38 | 61.22 | 63.64 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Xencor, Inc.this co. | XNCR | $890M | - | 1.40 | -14.5% | - |
| ARS Pharmaceuticals, Inc. | SPRY | $901M | -5.26 | 7.88 | -149.9% | -5.66 |
| Annexon, Inc. | ANNX | $893M | -4.32 | 4.22 | -97.7% | -3.54 |
| Pacira BioSciences, Inc. | PCRX | $892M | 126.89 | 1.29 | 1.0% | 8.75 |
| Cullinan Therapeutics, Inc. | CGEM | $887M | -4.03 |
| - |
| - |
| - |
| - |
| 2.17 |
| -53.8% |
| -3.32 |
| MeiraGTx Holdings plc | MGTX | $886M | -7.76 | -152.99 | 1971.4% | -10.17 |
| Jade Biosciences, Inc. | JBIO | $876M | - | -18.71 | -38.3% | - |
| Certara, Inc. | CERT | $873M | -547.16 | 0.82 | -0.2% | 9.65 |
| Talkspace, Inc. | TALK | $871M | 111.78 | 7.44 | 6.7% | 129.10 |
| Peer Median | - | -4.32 | 1.73 | -19.2% | -3.32 | |
Historically, Sep has averaged the highest return (+9.2%); Mar the lowest (-13.6%).
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -21.0%Negative MonthJan 2026: -21.03% | +5.6%Positive MonthFeb 2026: +5.62% | -5.6%Negative MonthMar 2026: -5.56% | -1.1%Neutral MonthApr 2026: -1.08% | -0.4%Neutral MonthMay 2026: -0.42% | +35.5%Positive MonthJun 2026: +35.52% | +25.5%Positive MonthJul 2026: +25.53% | +36.2%*Positive MonthAug 2026: +36.17% | — | — | — | — |
| 2025 | -20.5%Negative MonthJan 2025: -20.45% | -16.0%Negative MonthFeb 2025: -15.97% | -30.7%Negative MonthMar 2025: -30.73% | +3.6%Positive MonthApr 2025: +3.57% | -27.4%Negative MonthMay 2025: -27.40% | -1.7%Neutral MonthJun 2025: -1.75% | +5.9%Positive MonthJul 2025: +5.85% | -2.3%Negative MonthAug 2025: -2.28% | +44.3%Positive MonthSep 2025: +44.28% | +25.4%Positive MonthOct 2025: +25.40% | +17.7%Positive MonthNov 2025: +17.74% | -11.6%Negative MonthDec 2025: -11.61% |
| 2024 | -11.9%Negative MonthJan 2024: -11.92% | +22.7%Positive MonthFeb 2024: +22.73% | -3.6%Negative MonthMar 2024: -3.57% | -5.4%Negative MonthApr 2024: -5.38% | +13.5%Positive MonthMay 2024: +13.47% | -20.3%Negative MonthJun 2024: -20.33% | +7.9%Positive MonthJul 2024: +7.87% | -14.3%Negative MonthAug 2024: -14.35% | +15.0%Positive MonthSep 2024: +14.98% | +4.5%Positive MonthOct 2024: +4.48% | +21.8%Positive MonthNov 2024: +21.85% | -10.2%Negative MonthDec 2024: -10.23% |
| 2023 | +26.4%Positive MonthJan 2023: +26.42% | -2.4%Negative MonthFeb 2023: -2.40% | -13.2%Negative MonthMar 2023: -13.20% | -5.2%Negative MonthApr 2023: -5.20% | +2.5%Positive MonthMay 2023: +2.50% | -7.9%Negative MonthJun 2023: -7.86% | -2.7%Negative MonthJul 2023: -2.72% | -9.5%Negative MonthAug 2023: -9.51% | -8.3%Negative MonthSep 2023: -8.33% | -13.9%Negative MonthOct 2023: -13.90% | +5.7%Positive MonthNov 2023: +5.71% | +15.8%Positive MonthDec 2023: +15.76% |
| 2022 | -14.3%Negative MonthJan 2022: -14.33% | -8.9%Negative MonthFeb 2022: -8.90% | -14.8%Negative MonthMar 2022: -14.79% | -6.4%Negative MonthApr 2022: -6.37% | -10.6%Negative MonthMay 2022: -10.61% | +22.6%Positive MonthJun 2022: +22.57% | +4.8%Positive MonthJul 2022: +4.82% | -8.0%Negative MonthAug 2022: -8.02% | -1.6%Neutral MonthSep 2022: -1.55% | +7.8%Positive MonthOct 2022: +7.78% | +6.1%Positive MonthNov 2022: +6.14% | -12.4%Negative MonthDec 2022: -12.38% |
| 2021 | — | — | — | — | -9.6%Negative MonthMay 2021: -9.63% | -10.3%Negative MonthJun 2021: -10.32% | -10.8%Negative MonthJul 2021: -10.76% | +10.0%Positive MonthAug 2021: +10.04% | -3.6%Negative MonthSep 2021: -3.57% | +21.1%Positive MonthOct 2021: +21.13% | -8.4%Negative MonthNov 2021: -8.44% | +10.8%Positive MonthDec 2021: +10.77% |
| Avg±SD |
Each cell is the percentage change in closing price from the end of the prior month to the end of this month. The bottom row shows the average return for that calendar month across the selected years, plus or minus one standard deviation — the range that historically contained roughly two-thirds of outcomes. Past monthly patterns are not a forecast of future returns.
This aggregates every month by calendar position — all Januaries together, all Februaries together, and so on — to show whether a given month has leaned positive or negative historically. ‘Simple’ counts each month as +1 or −1. ‘Weighted’ gives larger moves more influence: +2 above +10%, −2 below −10%. With only 6 years of history for this asset, each month’s score reflects a small number of observations — read it as a historical tendency, not a reliable seasonal pattern.
This tracks a running tally across the asset’s full price history: each month adds or subtracts based on whether it was positive or negative. A rising line means more positive months than negative so far; a flattening or falling line means recent months have leaned negative. This measures historical month-to-month consistency, not expected future performance.
Year-to-date return is calculated by dividing each day’s closing price by the price on January 1st of that year (or the asset’s first available price if it began trading mid-year). The custom average line shows the mean YTD return at each calendar day across the selected years. The standard deviation band shows the range within which returns have historically fallen — at 1 SD, roughly two-thirds of years; at 2 SD, roughly 95%. Past year-to-date patterns do not predict future returns. The average and standard deviation band are computed from the year set chosen in “Average from”, which is independent of which year lines are displayed. The current in-progress year is excluded from these calculations, since a partial year is not comparable to complete ones. Election-cycle groupings follow the US presidential calendar and are offered only for US and crypto assets.
